Welcome to our dedicated page for Cingulate news (Ticker: CING), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.
Cingulate Inc. (NASDAQ: CING) generates frequent news as a clinical-stage biopharmaceutical company advancing its Precision Timed Release™ (PTR™) platform and lead ADHD candidate, CTx-1301. This news page aggregates company press releases, analyst coverage, and regulatory updates so readers can follow key developments in Cingulate’s late-stage clinical and regulatory journey.
Recent announcements highlight major milestones for CTx-1301, including submission and FDA acceptance of the New Drug Application under the 505(b)(2) pathway, assignment of a Prescription Drug User Fee Act (PDUFA) target action date, and positive Phase 3 trial results in adult and pediatric ADHD populations. News items also cover presentations of clinical data at scientific meetings, such as podium presentations at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting.
Investors and followers of CING can use this page to track quarterly financial results, capital-raising transactions, and material agreements disclosed through press releases and referenced in Form 8-K filings. Examples include commercial supply agreements with Bend Bio Sciences, commercialization partnerships with Indegene, and financing arrangements such as promissory notes and equity purchase agreements.
Corporate updates, including executive appointments in commercial leadership and board-level changes, are also reflected in Cingulate’s news flow. Together, these items provide context on how the company is preparing for potential commercialization of CTx-1301 and expanding its PTR-based pipeline in ADHD, anxiety, and other neuropsychiatric indications. Bookmark this page to review new CING headlines, clinical data disclosures, regulatory milestones, and business updates as they are released.
Cingulate Inc. has successfully completed its Initial Public Offering, raising gross proceeds of $25 million. This funding aims to advance its lead investigational drug, CTx-1301, for treating ADHD, with plans to file a New Drug Application with the FDA in late 2023. The company has updated its clinical program to streamline research, potentially reducing costs and approval time. As of December 31, 2021, cash reserves stood at $16.5 million, enabling funding through late 2022.
KANSAS CITY, Kan., Feb. 15, 2022 – Cingulate Inc. (NASDAQ: CING) has announced that CEO Shane J. Schaffer will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 10:30 a.m. ET. Cingulate's presentation will be available for viewing from February 23 to February 25. The clinical-stage biopharmaceutical company focuses on its Precision Timed Release™ (PTR™) drug delivery technology to develop products addressing ADHD and other conditions. A webcast of the presentation will be available for 30 days after the event on Cingulate’s website.
Cingulate Inc. (NASDAQ: CING) has announced an expedited 2022 clinical program for its lead candidate, CTx-1301, aimed at treating ADHD. The company plans to initiate Phase 3 studies, including pediatric safety and efficacy assessments, in the second quarter of 2022. This acceleration, based on FDA feedback, is expected to lower capital requirements and expedite the New Drug Application filing anticipated in the latter half of 2023. Cingulate aims to enhance patient outcomes through its proprietary Precision Timed Release technology.
Cingulate Inc., a clinical-stage biopharmaceutical company, announced the appointment of Curt Medeiros and Gregg Givens to its Board of Directors following its IPO. Medeiros brings expertise in healthcare growth and market access, while Givens has over 35 years of finance experience. Both will contribute to the company’s vision of enhancing ADHD treatment and addressing unmet patient needs. Their backgrounds aim to strengthen Cingulate's leadership and business strategy as it advances its product pipeline, particularly targeting behavioral health and ADHD management.
Cingulate Inc. completed a $25 million Initial Public Offering (IPO) of Common Stock, facilitated by Aegis Capital Corp. as the Lead Bookrunning Manager. The company is focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) technology, particularly for treating Attention Deficit/Hyperactivity Disorder (ADHD). Their products aim to offer improved treatment outcomes and daily dosing regimens. Cingulate's pipeline includes innovative formulations like CTx-1301 and CTx-1302, designed for rapid onset and extended efficacy.
Cingulate Inc. has successfully completed its initial public offering, selling 4,166,666 shares of common stock along with warrants, generating approximately $25 million in gross proceeds. The shares and warrants now trade on the Nasdaq under the symbols ‘CING’ and ‘CINGW’, respectively. The funds will primarily support research and development for their product candidates, including CTx-1301 and CTx-1302, and cover various financial obligations. An over-allotment option was partially exercised, allowing for the sale of additional shares and warrants.
Cingulate Inc. has priced its initial public offering (IPO) of 4,166,666 shares at $6.00 per share, paired with warrants at the same price. The offering will yield gross proceeds of approximately $25 million, aimed at advancing its clinical products, including CTx-1301 and CTx-1302, focused on ADHD treatment. The shares and warrants are set to trade on Nasdaq under the symbols ‘CING’ and ‘CINGW’ starting December 8, 2021. The transaction is expected to close on December 10, 2021, if standard conditions are met.